UA99626C2 - Соединения хинолина, пригодные для лечения нарушений, реагирующих на модуляцию рецептора 5-нт6 серотонина - Google Patents

Соединения хинолина, пригодные для лечения нарушений, реагирующих на модуляцию рецептора 5-нт6 серотонина

Info

Publication number
UA99626C2
UA99626C2 UAA201002519A UAA201002519A UA99626C2 UA 99626 C2 UA99626 C2 UA 99626C2 UA A201002519 A UAA201002519 A UA A201002519A UA A201002519 A UAA201002519 A UA A201002519A UA 99626 C2 UA99626 C2 UA 99626C2
Authority
UA
Ukraine
Prior art keywords
serotonin
respond
modulation
receptor
quinoline compounds
Prior art date
Application number
UAA201002519A
Other languages
English (en)
Ukrainian (uk)
Inventor
Шон Кольм ТЕРНЕР
Вильфрид БРАЙЕ
Андреас ХАУПТ
Удо ЛАНГЕ
Карла ДРЕШЕР
Карстен ВИККЕ
Лилиане УНГЕР
Марио МЕЦЛЕР
Вольфганг ВЕРНЕТ
Маттиас МАЙРЕР
Original Assignee
Эбботт Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Гмбх Унд Ко. Кг filed Critical Эбботт Гмбх Унд Ко. Кг
Publication of UA99626C2 publication Critical patent/UA99626C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Данное изобретение касается соединений хинолина формулы (I) и их солей. Эти соединения имеют полезные терапевтические свойства и являются особенно пригодными для лечения заболеваний, отвечаюших на модуляцию рецептора серотонина 5-НТ. В формуле (I) R означает группу формулы (R), в которой * указывает сайт связывания с хинолинильным радикалом и в которой А, В, X’, Y, Q, R, R, R, R, R, m, n, p, q, Ra, Rb, X и Ar имеют значения, определенные в п. 1 формулы изобретения.
UAA201002519A 2007-08-07 2008-08-06 Соединения хинолина, пригодные для лечения нарушений, реагирующих на модуляцию рецептора 5-нт6 серотонина UA99626C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113962 2007-08-07

Publications (1)

Publication Number Publication Date
UA99626C2 true UA99626C2 (ru) 2012-09-10

Family

ID=39809897

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201002519A UA99626C2 (ru) 2007-08-07 2008-08-06 Соединения хинолина, пригодные для лечения нарушений, реагирующих на модуляцию рецептора 5-нт6 серотонина

Country Status (23)

Country Link
US (2) US8293913B2 (ru)
EP (1) EP2185555B1 (ru)
JP (1) JP5501230B2 (ru)
KR (1) KR20100039300A (ru)
CN (1) CN101687866B (ru)
AU (1) AU2008285652B2 (ru)
BR (1) BRPI0812853A2 (ru)
CA (1) CA2691529C (ru)
CO (1) CO6251268A2 (ru)
CR (1) CR11187A (ru)
DO (1) DOP2009000291A (ru)
EC (1) ECSP099831A (ru)
ES (1) ES2574154T3 (ru)
GT (1) GT200900333A (ru)
HK (1) HK1143588A1 (ru)
IL (1) IL202706A (ru)
MX (1) MX2009013956A (ru)
NZ (1) NZ581986A (ru)
RU (1) RU2483068C2 (ru)
TW (1) TWI478919B (ru)
UA (1) UA99626C2 (ru)
WO (1) WO2009019286A1 (ru)
ZA (1) ZA200909075B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
MY187449A (en) 2013-11-26 2021-09-22 Hoffmann La Roche New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
HUE046820T2 (hu) 2014-03-26 2020-03-30 Hoffmann La Roche Biciklusos vegyületek autotaxin (ATX) és lizofoszfatidsav (LPA) termelésgátlókként
KR102390045B1 (ko) * 2014-04-30 2022-04-22 카티바, 인크. 가스 쿠션 장비 및 기판 코팅 기술
CR20180058A (es) 2015-09-04 2018-02-26 Hoffmann La Roche Nuevos derivados de fenoximetilo
CN107922415B (zh) 2015-09-24 2022-04-15 豪夫迈·罗氏有限公司 新的作为双重atx/ca抑制剂的二环化合物
MX2018001890A (es) 2015-09-24 2018-06-20 Hoffmann La Roche Compuestos biciclicos como inhibidores de autotaxina (atx).
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
MX2017015034A (es) * 2015-09-24 2018-04-13 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
AR106515A1 (es) * 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
WO2017157929A1 (en) * 2016-03-14 2017-09-21 AbbVie Deutschland GmbH & Co. KG Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
CR20190423A (es) 2017-03-16 2019-11-01 Hoffmann La Roche Nuevos compuestos biciclícos como inhibidores dobles de atx/ca
CN112010859B (zh) * 2019-05-30 2022-07-19 中国科学院上海药物研究所 一种并环化合物、其制备方法和用途
WO2022272106A1 (en) * 2021-06-26 2022-12-29 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9611479B1 (pt) 1995-11-13 2009-01-13 Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
DE10000739A1 (de) * 2000-01-11 2001-07-12 Merck Patent Gmbh Piperidin- und Piperazinderivate
KR101020399B1 (ko) 2002-03-27 2011-03-08 글락소 그룹 리미티드 퀴놀린 유도체 및 5-ｈｔ6 리간드로서의 그의 용도
GB0321473D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) * 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
BRPI0415683A (pt) * 2003-11-03 2006-12-19 Warner Lambert Co inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
DE102004038268A1 (de) * 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0425548D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands
CA2606288A1 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
JP2009502853A (ja) * 2005-07-27 2009-01-29 エフ．ホフマン−ラ ロシュ アーゲー アリールオキシキノリン類及び５−ｈｔ６モジュレーターとしてのその使用
GB0519765D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
CA2691529A1 (en) 2009-02-12
IL202706A (en) 2014-08-31
RU2483068C2 (ru) 2013-05-27
AU2008285652B2 (en) 2013-09-05
GT200900333A (es) 2015-10-14
TW200914453A (en) 2009-04-01
KR20100039300A (ko) 2010-04-15
NZ581986A (en) 2012-02-24
US20130005703A1 (en) 2013-01-03
TWI478919B (zh) 2015-04-01
WO2009019286A1 (en) 2009-02-12
US8293913B2 (en) 2012-10-23
CA2691529C (en) 2016-01-05
CN101687866A (zh) 2010-03-31
JP2010535739A (ja) 2010-11-25
JP5501230B2 (ja) 2014-05-21
CO6251268A2 (es) 2011-02-21
HK1143588A1 (zh) 2011-01-07
US8440694B2 (en) 2013-05-14
CR11187A (es) 2010-05-27
DOP2009000291A (es) 2010-01-31
ZA200909075B (en) 2013-03-27
CN101687866B (zh) 2014-06-04
AU2008285652A1 (en) 2009-02-12
IL202706A0 (en) 2010-06-30
EP2185555B1 (en) 2016-03-16
EP2185555A1 (en) 2010-05-19
US20100292271A1 (en) 2010-11-18
MX2009013956A (es) 2010-04-30
ES2574154T3 (es) 2016-06-15
RU2010108282A (ru) 2011-09-20
BRPI0812853A2 (pt) 2014-12-23
ECSP099831A (es) 2010-01-29

Similar Documents

Publication Publication Date Title
UA99626C2 (ru) Соединения хинолина, пригодные для лечения нарушений, реагирующих на модуляцию рецептора 5-нт6 серотонина
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
EA200601266A1 (ru) Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
UA93872C2 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
WO2008019967A3 (en) Phenyl, pyridine and quinoline derivatives
EG26020A (en) Derivatives 3- (Hetero Aryl-AXY) -2- Alkyl -1- AZA Dicyclic Alkyl Carbides Alpha 7- NACHR for the treatment of diseases of the central nervous system
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
MX2009013592A (es) Proceso para la preparacion de pirazoles.
GEP201706639B (en) Heterocyclic compounds and uses thereof
TW200630374A (en) Thiazolyldihydroindazoles
TW200628154A (en) Organic compounds
MX2010003346A (es) Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
MY153719A (en) Prokineticin 1 receptor antagonists
MX2009013129A (es) Derivados de indazolamida.
MY149934A (en) 4-substituted phenoxyphenylacetic acid derivatives
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
ATE407120T1 (de) 3-((hetero)arylsulfonyl)-8- ä(aminoalkyl)oxyüchinoline als antagonisten des 5-ht6-rezeptors zur behandlung von erkrankungen des zns
ATE521609T1 (de) Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MX2007000576A (es) Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias.
GB0519760D0 (en) Novel compounds
NO20075477L (no) Tetrahydro-pyridoazepin-8-one og beslektede forbindelser for behandling av schizofreni
SI1745010T1 (sl) Substituirani cikloheksil-1,4-diaminski derivati
MX2009010243A (es) Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.